GALDERMA GROUP AG (NYSE: GALDY) — Company Overview, News & Financial Data
GALDERMA GROUP AG is a Switzerland-based pure-play dermatology company specializing in research, development, and commercialization of skin care solutions across three core product categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology.
GALDERMA GROUP AG
GALDERMA GROUP AG is a Switzerland-based pure-play dermatology company specializing in research, development, and commercialization of skin care solutions across three core product categories: Injectable Aesthetics, Dermatological Skincare, and Therapeutic Dermatology. Its commercial portfolio includes hyaluronic acid dermal fillers, neuromodulators, biostimulators, daily skin health products, and prescription treatments for dermatological conditions such as acne, rosacea, atopic dermatitis, and psoriasis. Operating globally with dedicated research and development centers and manufacturing facilities in Europe, North America, and South America, the organization distributes its therapeutic and aesthetic products across more than ninety countries to consumers and healthcare professionals.
Snapshot
Operations
Products and/or services of GALDERMA GROUP AG
- Injectable Aesthetics - Dermal Fillers and Biostimulators: Formulates and manufactures hyaluronic acid dermal fillers and poly-L-lactic acid biostimulators, including Restylane and Sculptra, designed for facial aesthetic restoration, tissue volume enhancement, and collagen stimulation distributed across global markets.
- Injectable Aesthetics - Neuromodulators: Produces botulinum toxin type A injectable treatments, such as Dysport, Alluzience, and Relfydess, supplying specialized clinics and healthcare professionals worldwide for temporary smoothing of moderate-to-severe glabellar lines and facial dynamic wrinkles.
- Dermatological Skincare - Dermo-Cosmetics: Develops, manufactures, and distributes scientifically formulated daily cleansers, moisturizers, and sun protection lines, including Cetaphil and Alastin Skincare, catering to sensitive, damaged, and post-procedure skin across retail and clinical channels globally.
- Therapeutic Dermatology - Topical Acne and Rosacea Therapies: Provides prescription topical dermatological formulations, including Differin, Epiduo, Soolantra, and Aklief, targeting inflammatory skin conditions, acne vulgaris, and rosacea through widespread distribution networks in hospitals, pharmacies, and specialty dermatology clinics.
- Therapeutic Dermatology - Biologics and Immuno-Dermatology: Commercializes targeted monoclonal antibody biological therapies, including Nemluvio, for chronic inflammatory skin disorders such as moderate-to-severe atopic dermatitis and prurigo nodularis, expanding clinical treatments across major pharmaceutical markets globally.
- Global Manufacturing and Research Infrastructure: Operates specialized pharmaceutical manufacturing plants and R&D centers located in Alby in Sweden, Baie-D'Urfé in Canada, Hortolândia in Brazil, and Zug in Switzerland, producing sterile injectables, topical creams, gels, and liquids.
GALDERMA GROUP AG executive team
- Dr. Flemming Ornskov M.B.A., M.D., M.P.H.CEO & Director
- Mr. Thomas J. W. DittrichChief Financial Officer
- Mr. Adrian MurphyHead of Global Operations
- Mr. Emil IvanovHead of Strategy, Investor Relations & ESG
- Mr. Christian MarcouxChief Communications Officer
- Ms. Allison PinkhamChief Human Resources Officer